These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35573949)

  • 1. Intravenous Immunoglobulin Use in Hemolytic Disease Due to ABO Incompatibility to Prevent Exchange Transfusion.
    Okulu E; Erdeve O; Kilic I; Olukman O; Calkavur S; Buyukkale G; Cetinkaya M; Ulubas D; Demirel N; Hanta D; Ertugrul S; Gultekin ND; Tuncer O; Demir N; Bilgin L; Narli N; Yildiz D; Terek D; Koroglu OA; Seren C; Ozyazici E; Ozdemir R; Turgut H; Narter F; Akin Y; Ozyazici A; Zenciroglu A; Asker HS; Gokmen Z; Salihli M; Bulbul A; Zubarioglu U; Atasay B; Koc E;
    Front Pediatr; 2022; 10():864609. PubMed ID: 35573949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates.
    Demirel G; Akar M; Celik IH; Erdeve O; Uras N; Oguz SS; Dilmen U
    Int J Hematol; 2011 Jun; 93(6):700-703. PubMed ID: 21617887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Immunoglobulin G Treatment in ABO Hemolytic Disease of the Newborn, is it Myth or Real?
    Beken S; Hirfanoglu I; Turkyilmaz C; Altuntas N; Unal S; Turan O; Onal E; Ergenekon E; Koc E; Atalay Y
    Indian J Hematol Blood Transfus; 2014 Mar; 30(1):12-5. PubMed ID: 24554813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin for alloimmune hemolytic disease in neonates.
    Zwiers C; Scheffer-Rath ME; Lopriore E; de Haas M; Liley HG
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD003313. PubMed ID: 29551014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Immunoglobulins as Adjunct Treatment to Phototherapy in Isoimmune Hemolytic Disease of the Newborn: A Retrospective Case-Control Study.
    Al-Lawama M; Badran E; Elrimawi A; Bani Mustafa A; Alkhatib H
    J Clin Med Res; 2019 Nov; 11(11):760-763. PubMed ID: 31803318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn.
    Nasseri F; Mamouri GA; Babaei H
    Saudi Med J; 2006 Dec; 27(12):1827-30. PubMed ID: 17143357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intravenous immunoglobulin on the management of Rh- and ABO-mediated hemolytic disease of the newborn.
    Jalali SZ; Mahdipour S; Asgarzad R; Saadat F
    Hematol Transfus Cell Ther; 2024 Apr; ():. PubMed ID: 38719722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study.
    Pan J; Zhan C; Yuan T; Chen X; Ni Y; Shen Y; Chen W; Wu T; Yu H
    J Perinatol; 2021 Jun; 41(6):1397-1402. PubMed ID: 33589732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn.
    Miqdad AM; Abdelbasit OB; Shaheed MM; Seidahmed MZ; Abomelha AM; Arcala OP
    J Matern Fetal Neonatal Med; 2004 Sep; 16(3):163-6. PubMed ID: 15590442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An early (sixth-hour) serum bilirubin measurement is useful in predicting the development of significant hyperbilirubinemia and severe ABO hemolytic disease in a selective high-risk population of newborns with ABO incompatibility.
    Sarici SU; Yurdakök M; Serdar MA; Oran O; Erdem G; Tekinalp G; Yiğit S
    Pediatrics; 2002 Apr; 109(4):e53. PubMed ID: 11927726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Description of IVIG Use in Term Neonates with ABO Incompatibility.
    Daunov M; Schlosser A; Malay S; Adams J; Clark R; Ferrerosa L; Pateva I
    Am J Perinatol; 2024 Mar; ():. PubMed ID: 38286423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three or four doses of intravenous immunoglobulin G treatment for isoimmune hemolytic disease: A case series and literature review.
    Zheng Y; Almeyda-Alejo Y; Tumin D; Redpath NSJ; Guillen-Hernandez J
    J Neonatal Perinatal Med; 2024; 17(1):153-158. PubMed ID: 38143377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial.
    Elalfy MS; Elbarbary NS; Abaza HW
    Eur J Pediatr; 2011 Apr; 170(4):461-7. PubMed ID: 20924607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Intravenous Immunoglobulin Administration for Hyperbilirubinemia in Newborn Infants with Hemolytic Disease.
    Mohan DR; Lu H; McClary J; Marasch J; Nock ML; Ryan RM
    Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravenous immunoglobulin in the management of haemolytic disease of the newborn.
    Walsh SA; Yao N; El-Khuffash A; Twomey A; Molloy EJ
    Ir Med J; 2008 Feb; 101(2):46-8. PubMed ID: 18450249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple dose IVIG treatment in neonatal immune hemolytic jaundice.
    Tanyer G; Siklar Z; Dallar Y; Yildirmak Y; Tiraş U
    J Trop Pediatr; 2001 Feb; 47(1):50-3. PubMed ID: 11245352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.
    Lieberman L; Lopriore E; Baker JM; Bercovitz RS; Christensen RD; Crighton G; Delaney M; Goel R; Hendrickson JE; Keir A; Landry D; La Rocca U; Lemyre B; Maier RF; Muniz-Diaz E; Nahirniak S; New HV; Pavenski K; Dos Santos MCP; Ramsey G; Shehata N;
    Br J Haematol; 2022 Jul; 198(1):183-195. PubMed ID: 35415922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis].
    Cortey A; Elzaabi M; Waegemans T; Roch B; Aujard Y
    Arch Pediatr; 2014 Sep; 21(9):976-83. PubMed ID: 25125032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah's Witness newborns as an alternative to exchange transfusion.
    Kappas A; Drummond GS; Munson DP; Marshall JR
    Pediatrics; 2001 Dec; 108(6):1374-7. PubMed ID: 11731664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Meta analysis of the effect of immunoglobulin infusion on neonatal isoimmune hemolytic disease caused by blood group incompatibility].
    Li ZH; Wang J; Chen C
    Zhonghua Er Ke Za Zhi; 2010 Sep; 48(9):656-60. PubMed ID: 21092522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.